BACKGROUND: Pancreatic cancer remains one of the most lethal of all solid tumours of the gastrointestinal tract. It is characterized by late diagnosis, aggressive local invasion, early metastasis and resistance to chemoradiotherapy. Increasing knowledge regarding the molecular events behind the growth and invasion of pancreatic cancer may lead to new targets for intervention. METHODS: A search of Pubmed and Medline databases was undertaken using the keywords pancreatic cancer, gastrointestinal cancer, hypoxia, angiogenesis and anti-angiogenesis therapy. RESULTS: Hypoxia is the driving force behind angiogenesis in pancreatic cancers. Research into angiogenesis has shown many different sites that can be targeted by agents such as tyrosine kinase inhibitors. CONCLUSION: Anti-angiogenic therapy could be an important adjunct to conventional chemotherapy treatment of gastrointestinal neoplasia.
BACKGROUND:Pancreatic cancer remains one of the most lethal of all solid tumours of the gastrointestinal tract. It is characterized by late diagnosis, aggressive local invasion, early metastasis and resistance to chemoradiotherapy. Increasing knowledge regarding the molecular events behind the growth and invasion of pancreatic cancer may lead to new targets for intervention. METHODS: A search of Pubmed and Medline databases was undertaken using the keywords pancreatic cancer, gastrointestinal cancer, hypoxia, angiogenesis and anti-angiogenesis therapy. RESULTS:Hypoxia is the driving force behind angiogenesis in pancreatic cancers. Research into angiogenesis has shown many different sites that can be targeted by agents such as tyrosine kinase inhibitors. CONCLUSION: Anti-angiogenic therapy could be an important adjunct to conventional chemotherapy treatment of gastrointestinal neoplasia.
Authors: Min Li; Yuqing Zhang; Uddalak Bharadwaj; Qihui Jim Zhai; Charlotte H Ahern; William E Fisher; F Charles Brunicardi; Craig D Logsdon; Changyi Chen; Qizhi Yao Journal: Clin Cancer Res Date: 2009-09-15 Impact factor: 12.531
Authors: Melissa L Fishel; Yanlin Jiang; N V Rajeshkumar; Glenda Scandura; Anthony L Sinn; Ying He; Changyu Shen; David R Jones; Karen E Pollok; Mircea Ivan; Anirban Maitra; Mark R Kelley Journal: Mol Cancer Ther Date: 2011-06-23 Impact factor: 6.261
Authors: T Dragovich; D Laheru; F Dayyani; V Bolejack; L Smith; J Seng; H Burris; P Rosen; M Hidalgo; P Ritch; A F Baker; N Raghunand; J Crowley; D D Von Hoff Journal: Cancer Chemother Pharmacol Date: 2014-06-18 Impact factor: 3.333
Authors: Min Li; Yuqing Zhang; Zijuan Liu; Uddalak Bharadwaj; Hao Wang; Xinwen Wang; Sheng Zhang; Juan P Liuzzi; Shou-Mei Chang; Robert J Cousins; William E Fisher; F Charles Brunicardi; Craig D Logsdon; Changyi Chen; Qizhi Yao Journal: Proc Natl Acad Sci U S A Date: 2007-11-14 Impact factor: 11.205
Authors: Yuqing Zhang; Uddalak Bharadwaj; Craig D Logsdon; Changyi Chen; Qizhi Yao; Min Li Journal: Clin Cancer Res Date: 2010-02-16 Impact factor: 12.531
Authors: J R Tysome; A Briat; G Alusi; F Cao; D Gao; J Yu; P Wang; S Yang; Z Dong; S Wang; L Deng; J Francis; T Timiryasova; I Fodor; N R Lemoine; Y Wang Journal: Gene Ther Date: 2009-07-09 Impact factor: 5.250